Ondine Biomedical Share Discussion Threads

[nigoil] 26/4/2024 07:05

How are your 2.3p PPP shares doing purple11?...... LOL

Simples!....... :-)

[jailbird] 25/4/2024 22:04

ScrutableI have already embarrassed you about your CPX holding It is not cheap on fundamentals plus dilution on its way No doubt there is potential here but small emerging companies always have potential , it is whether the BoD have the expertise to deliver it to reach a wider commercialisation model There is hope here for sure , so if you are buying around here , you may be ok longer term .You have joined the discussion late so do not start preaching

[scrutable] 25/4/2024 21:28

MRSA bacteria are frightening. It is more and more difficult to find biocidal sprays which are effective in supressing them after surgery and recovery from heavy surgery is more and more compromised.
It may be an exaggeration to assert that this photo disinfection comes almost "in the nick of time" but not by very much. It offers a jump step in surgery. One without peer or competition.
Those who measure the economy in numbers will have noticed that the first flush of orders are seeded widely across the world and re-orders will ,I am certain, be exponential rather than turgidly linear. The market expansion coefficient just needs an order by a leading health institution inJapan, better still in Singapore and Hong Kong as well, which wil lead quickly into China. Then. Ondine ll be well away to the races. The last fly in the ointment is the 19th century approach to medical innovation at the FDA who I believe insist that any advance be first proven to be trouble free on animals and is incompatible with the speed of technology across the USA.

Ondine looks surprisingly cheap ahead of so much potential.

[purple11] 25/4/2024 10:21

they need to finalize funding promptly and put a floor under the price.

i will reveiw it once this has been done.atb

[molatovkid] 24/4/2024 07:36

Jailbird, you summarised my feelings 100%....no holding yet and only the financing putting me off. Definitely going places though

[bamboo2] 24/4/2024 07:27

Very crudely calculated, in 2023 16 hospitals produced $75,000 turnover each.

Like the partnership proposal.

[bamboo2] 24/4/2024 07:22

Corporate and Trading Update

Significant revenue growth and commercial momentum

Ondine Biomedical (LON: OBI), a leading provider of light-activated antimicrobial technology to treat and prevent hospital infections, provides an update on its recent developments, strategic priorities and 2024 corporate plans.

Commercial

In 2023, revenues nearly doubled to $1.2 million ($0.6 million in 2022), driven by significant growth in the number of hospitals deploying Steriwave®. Ondine ended the year with 16 hospital deployments, up from six at the prior year end. This momentum has continued with eight additional hospital deployments in Q1 2024, bringing the total to 24 hospitals, 50% up from the previous year-end and four times the number at the beginning of 2023.

During the last quarter, several hospitals announced expansions to include other surgical indications. The Company is also benefitting from significantly reduced sales cycle times, lower new client acquisition costs and improved margins resulting from lower cost of goods and higher product pricing. Retention of hospital accounts added to date is at 100%.

Of the eight new hospital placements in the first quarter of 2024, five of these were located internationally:

· In the UK, strategic inroads were made into the NHS in England with the accelerated adoption by two hospitals in the Mid Yorkshire NHS Teaching Trust (the "Trust") for orthopedic surgeries as a result of a strong early pilot data in one of them, and high levels of enthusiasm for the new technology by both healthcare professionals and patients. The Trust created a 12-month budget for the use of Steriwave for patients undergoing hip and knee surgery. Ondine is now partnering with the Trust and Health Innovation Yorkshire and Humber to conduct a health economic analysis to further support Steriwave adoption across the NHS. In the private sector, HCA Healthcare UK has approved Steriwave for use in its UK-based private hospitals, at the discretion of the clinician. HCA UK, a leading private healthcare provider in the UK with 30 facilities, is a subsidiary of HCA Healthcare (USA).

· In Spain, the first three hospitals are now implementing Steriwave, including the prestigious Hospital Universitario La Paz (HULP). HULP is a large tertiary hospital in Madrid with 1,308 beds. The Hospital Universitario La Paz is recognized as a centre of reference and health excellence and is considered one of the top three public hospitals with the best reputation in Spain.

· In Australia, Ondine has achieved its first hospital deployment in Australia at Mater Hospital, North Sydney, a 233-bed private hospital in New South Wales. The hospital is part of the St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services. This follows the recent Australian Spine Society Conference held from 5-7 April 2024, at which Dr. John Street, Co-Medical Director of the Complex Spine Program at Vancouver General Hospital, presented his research study findings on Steriwave as keynote speaker.

Distribution Partnership(s) to accelerate growth: As a result of Ondine's positive clinical data, growing sales momentum and recent commercial success, the Company has been approached by several multinational companies in the hospital supply, wound care, and infection control industries. The Company is currently in a process of progressing discussions on distribution collaborations with potential partners. While these discussions have been constructive, there is no certainty that a distribution agreement will materialize from any of these discussions. Management believes that distribution partnerships have the potential to generate earlier income for Ondine in the form of time-based territorial license payments and to accelerate sales and income generation for the Company through faster market penetration and greater geographical reach. The Company's 2023 investments in manufacturing capacity upgrades combined with a significant COGS reduction program support larger-scale rollout and increased gross margins required by any potential partners. The latest generation light diffuser is reducing the cost of goods for our Steriwave testing kits by 46 per cent.

Expansion into Intensive Care Units (ICU): Ondine is accelerating its plans to enter the ICU market to take advantage of interest by hospitals to replace the commonly used antibiotic mupirocin. Mupirocin, the topically applied antibiotic used in the nose over 5 days, requires lengthy administration times and generates antibiotic resistance. Having established a solid safety and efficacy profile in over 150,000 patients in pre-surgical and industrial settings, the Company estimates that the ICU application represents an opportunity to expand the total addressable market for Steriwave significantly. As ICUs have the highest hospital rates of infection and mortality, they represent an opportunity to accelerate new hospital adoption at a point of major unmet need both in terms of improving patient outcomes and reducing cost of care and length of stay. Further announcements will be made in due course.

US Phase 3 Clinical Trial Plans

Following a Type C meeting with the US Food & Drug Administration ("FDA") last September, the design and budget for the clinical trial program has been finalized in close collaboration with HCA Healthcare ("HCA"), Ondine's US clinical trial partner. The trial will run at 14 HCA hospital sites with a circa 5,000-patient group-randomized crossover study, comparing Ondine's nasal photodisinfection added to standard-of-care infection prevention practices versus standard-of-care alone. The Company is targeting to commence the trial in the third quarter of this year. Data from the trial will inform the Company's planned FDA submission and approval would facilitate adoption of Steriwave in the US.

Funding Position and Support

The Company has received indications of support from its founder CEO and substantial shareholder, Carolyn Cross, and from other existing shareholders, to provide near-term funding to extend the Company's runway. Discussions are currently underway with HCA's investment arm, Health Insight Capital, for its funding support of the key Phase 3 clinical trial. The Company is confident in its ability to secure longer-term financing to execute on the growth opportunities described above. Further announcements will be made in due course.

[jailbird] 24/4/2024 07:15

A comprehensive update They have a great tech here, they have something great here .now to find a way to turn this to multi million revenues . It is a challenge for them and need partners on board to expand the reach.Cash is the issue here and as potential investors that is what we think about How can raise this without impacting share price via dilution Also I bet their competitors will do what they can to prevent losing market share But Really they should looking to buy this company

[marvelman] 22/4/2024 11:50

Totally agree Bamboo.

[bamboo2] 22/4/2024 08:33

With all these RNSNON, it seems likely to me that the company is collecting a huge dossier of empirical evidence that will likely obviate the need for an extensive trial in the US. Benefits of a more limited US trial would be reduced costs and earlier acceptance.

[bamboo2] 22/4/2024 08:23

Steriwave in first Australian hospital

Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical's award-winning light-activated antimicrobial technology

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services.

Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of Medical Oncology at the University of Sydney, said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose - a major source of infection transmission - is a benefit to our patients."

Orthopaedic Spine Surgeon Dr John Street, Director of the Integrated Ambulatory Spine Program at Vancouver Coastal Health and upcoming President of the Canadian Spine Society, was a keynote speaker at the recent 2024 Spine Society of Australia 35th Annual Scientific Meeting that was held in Sydney on April 5-7th, 2024. Dr Street presented the results of his team's 14-year study evaluating Steriwave's effect on SSIs following spine surgery at Vancouver General Hospital ("VGH"), concluding that Steriwave nasal photodisinfection should be part of routine use and recommended it as standard of care for all elective and emergent spine surgeries.

The VGH research involved 13,493 patients and demonstrated a 66.5% reduction (7.98% vs 2.67%, p<0.001) in surgical site infections (SSIs) following spine surgery when Ondine's Steriwave nasal photodisinfection (nPDT) was implemented in the universal pre-surgical infection prevention protocol. The researchers also found average net annual cost saving of $2.49 million, a saving of over $2,400 per spine surgery patient, post rollout.

[premium beeks] 12/4/2024 13:21

On the staff noticeboard at Pinderfields - I've also posted in on the SHA thread.Our patients are the first in the country to be treated ahead of surgery with a new light- activated antimicrobial that kills all types of bugs including viruses, bacteria, and fungi, in minutes.This new treatment, called Steriwave, is used on hip and knee patients coming in for surgery at Pinderfields and Pontefract hospitals. It also helps to combat antimicrobial resistance.The Trust decided to roll out the technology after a successful trial at Pontefract Hospital last year.HTTPS://www.midyorks.nhs.uk/news/patients-to-be-treated-with-new-lightactivated-antimicrobial-3326

[marvelman] 10/4/2024 08:21

This is certainly a great product with massive potential. However. as we all know the company is poorly financed and that needs to be addressed urgently before many of us can be tempted back. A real shame it has got to this.

[oakville] 10/4/2024 08:10

Good to see some relief from the recent falls.

[jailbird] 10/4/2024 07:35

Good news but But we need numbers , all a bit hit and miss Usage depends on clinician at the time

[bamboo2] 10/4/2024 07:23

Steriwave authorized for use by HCA UK

Light-activated antimicrobial that does not generate antimicrobial resistance (AMR) approved for use in healthcare facilities operated by leading private healthcare provider HCA Healthcare UK

Leading private healthcare provider, HCA Healthcare UK, has approved the Steriwave® light-activated antimicrobial developed by Ondine Biomedical Inc. (LON:OBI) for use in its healthcare facilities to prevent healthcare-associated infections (HAIs) and reduce the use of antibiotics. HCA Healthcare is the largest private healthcare provider in the world, and one of the leading private healthcare providers in the UK, where it operates over 30 healthcare facilities.

Antimicrobial resistance (AMR) is a growing concern for healthcare providers around the world, particularly in the prevention and treatment of HAIs. Steriwave is a light-activated antimicrobial with a distinct mechanism of action from traditional antibiotics, allowing it to be used without fear of generating AMR. Its broad-spectrum efficacy destroys bacteria, viruses, and fungi in a single, 5-minute treatment.

Steriwave has already been successfully used in a small patient population in HCA Healthcare UK hospitals, but this approval will allow additional hospitals and healthcare facilities to adopt the technology more widely at the discretion of the clinician.

Professor Claire Hopkins, Professor of Rhinology at King's College London and Consultant ENT Surgeon at Guy's & St Thomas' NHS Foundation Trust and London Bridge Hospital, has used Steriwave routinely to nasally decolonise her endoscopic sinus surgery patients at HCA Healthcare UK's London Bridge Hospital since 2021. A retrospective study showed that using Steriwave in endoscopic sinus surgery patients led to antibiotic use across all her patients dropping from 22% to less than 5% - a 77% reduction.

Professor Hopkins commented: "I was amazed that studies show that by treating the nose you can reduce spinal surgical site infections - so it seemed an ideal way to reduce the risk of post-operative infection after nasal surgery. I have seen a significant reduction in post-operative infections requiring antibiotics, which is good for the patients, reducing the risk of antibiotic-related side effects, and important to help prevent ever-increasing antibiotic resistance. It needs formal controlled studies to further evaluate the effectiveness, but I am impressed with the difference that I have seen in my practice."

Interview with Professor Hopkins: Steriwave prevents sinonasal SSIs

Carolyn Cross, Ondine Biomedical CEO, commented: "We are delighted that Steriwave has now been authorized for use across HCA Healthcare UK's healthcare facilities. We are already working closely with HCA Healthcare in the US on our US Phase 3 trial and the FDA regulatory submission for Steriwave, so it is fantastic to be getting such good support from them in the UK as well. The study undertaken at London Bridge Hospital has demonstrated Steriwave's potential for addressing the threat of AMR by preventing infections and reducing antibiotic use."

HCA Healthcare is partnering with Ondine in the United States to conduct a US Phase 3 clinical trial with the ultimate goal of obtaining FDA approval to bring Ondine's nasal photodisinfection into the US market. HCA Healthcare operates 184 hospitals and over 2,000 sites of care across the United States, making it the largest healthcare system in the US.

[blackhorse23] 09/4/2024 09:19

Money moving to APH , excellent profitable healthcare company

[purple11] 09/4/2024 09:03

6.5 on the BID

it was always a possibility that it went this way
and with everyone running for the door at the same time it was going to be brutal and swift.loss of confidence.

[luzley] 05/4/2024 15:58

Agreed. The validity and need for Steriwave is proven but the current exposure and turnover is simply not enough to cover overheads. It absolutely needs a bigger player to scale this quickly and handle the Ph3 with HCA. The alternative of a deeply discounted rights issue would be impractical due to the capital required and dilution. Carolyn Cross CEO is highly regarded in Canadian Healthcare circles and at 62yrs old she must certainly have an exit strategy in place after so long at the helm.

[jailbird] 05/4/2024 14:06

Took a while for others to see what I was saying .So have you moved on or do you still have it on your watchlists ?

[blackhorse23] 05/4/2024 09:08

https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097